{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015779","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.757610+00:00","generated_at":"2026-05-29T23:36:01.425117+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path Q3 net loss $2.1M; expands DNAbilize into obesity; cash $0.6M","bullets":["Net loss of $2.1M ($0.70 per share) vs $3.2M ($6.36) in Q3 2023; R&D expense down to $1.3M from $2.3M.","Cash of $0.6M as of Sept 30, 2024 (Dec 31, 2023: $1.1M); operating cash burn $7.7M YTD 2024.","Initiated BP1001-A obesity program in October, first non-oncology application of DNAbilize technology targeting Grb2 insulin resistance.","Completed enrollment for third dose cohort of BP1002 Phase 1/1b trial in venetoclax-resistant AML patients ahead of schedule.","Closed $4.0M private placement in October: 4.6M shares and warrants at $0.87 per unit."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015779","json":"https://secwatch.observer/filing/0001558370-24-015779.json","markdown":"https://secwatch.observer/filing/0001558370-24-015779.md","text":"https://secwatch.observer/filing/0001558370-24-015779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024015779/0001558370-24-015779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024015779/bpth-20241115x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:36:01.425117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}